Mujaro price, differences and sale date

Munyauronew drug indicated for type 2 diabetes and obesityarrives in Spain to join his competitors. the best results today compared to those on the market, all thanks to the active ingredient: Tirzepatide.

“This is what makes the difference” and allows Muñaro to “strengthen” the results of semaglutide, the active ingredient in Ozempic and Vegovi, explained Javier Escalada, president of the Foundation of the Spanish Society of Endocrinology and Nutrition (FSEEN).

This has been achieved in overweight and obese people without diabetes figures that have so far only been achieved by bariatric surgery. Tirzepatide reduces an average of up to 22.5% of weight per week and, in addition, 4 out of 10 patients achieved a weight loss equal to or greater than 25%.

For diabetes, in studies, more than 90% of patients achieved glycemic control and more than half achieved normalization – compared with 19.7% who achieved this with semaglutide – with an average weight loss of up to 12.4 kg, double that of Ozempic . component, which is 6.2 kg.

General practice, 96% lost weight equal to or greater than 5% after 72 weeks of treatment. It also showed “impressive” results in reducing waist circumference by up to 20cm.

This weekly subcutaneous injection in doses of 5, 10 and 15 mg, although only the first two, the most used, will arrive in Spain for now.

Treatment begins stepwise with a dose of 2.5 mg for 4 weeks, then increases to 5 mg. If the expected results are not achieved, the dose is increased again to 7.5 mg for another four weeks, and then increased to 10, explained José Antonio Sacristán, medical director of Lilly Spain.

From next July 1 It will be available in Spanish pharmacies. Currently a new drug not funded

through the state system, although the company is located in negotiations with the Ministry of Health.

Until the funding that Health is considering is received, the price of Mujaro, which will be available in pharmacies only with a doctor’s prescription, will be 271 euros per month with treatment 5 mg, which with treatment 10 mg increases 358 euros each.

The main difference between terzapatide and semaglutide, which drugs such as Ozempic or Vegovi are based on, is that stimulates two and not alone hormone which helps control blood sugar levels and reduce appetite: in addition to glucagon-like peptide 1 (GLP-1), it activates glucose-dependent insulinotropic peptide (GIP).

Terzapatide – a recent study from the University of California, San Diego showed its potential as a first effective drug treatment for obstructive sleep apnea – it is contraindicated in people with a history of pancreatitis, as well as in pregnant women, since safety and effectiveness studies have not yet been conducted.

Munjaro was approved for two indications: for the treatment of type 2 diabetes, which affects one in seven adults in Spain, the second highest rate in Europe, and for weight control in people with a body mass index (BMI) over 27 and with one complication. caused by overweight or obesity -BMI over 30-. The mechanism of its action, in addition to promoting glycemic controldoes reduce appetiteincreases the feeling of fullness and reduces excess fat.

“This is for decidedly sick people: We’re not talking about periodic weight loss. go to the fair,” said Mar Malagon, president of the Spanish Society for the Fight against Obesity (Seedo), recalling that obesity is a chronic and multifactorial disease based on the dysfunction of adipose tissue, which affects 18% of adults in Spain.

What you need to understand about these drugs that are misused to shed a few pounds is that “if you don’t need them, they won’t do you any good. Changing the entire hormonal system can lead to harmful effects

in the long term,” he warned.

One of its side effects is loss of muscle mass -which can and should be mitigated by physical exercise, although weight loss is three times greater. Others are mild and very similar to semaglutide, such as nausea, diarrhea and vomiting. Only 4.2% of patients had to refuse treatment.

The responsible laboratory is American. Eli Lilly which will allocate an additional €4.895 million to its manufacturing plant in Indiana (USA), thereby increasing the company’s total investment in the facility to €8.311 million, the company said. “This expansion will expand Lilly’s capabilities to produce active pharmaceutical ingredients (APIs) for Zepbound (tirzepatide) and Mounjaro (tirzepatide) injections so more adults with chronic diseases such as obesity and type 2 diabetes can benefit from these important treatments.” , they explained at a press conference today.